MTOR and nonpapillary renal cell carcinoma: Patients with ccRCC and with distant metastasis almost lose the indication of surgery, and mainly rely on conservative treatment; their 5-year survival rate is <10% despite the use of one or more combination therapies, including cytoreductive nephrectomy or metastasectomy, VEGFR inhibitors, mTOR inhibitors, and immunotherapy (5).